• admin@ataxiatelangiectasia.es
ataksi telenjiektazi
  • Başlangıç
  • A-T nedir?
  • Anti-peptide Antibody Responses in Patients with Ataxia-telangiectasia
  • Ataxia-telangiectasia: Immunodeficiency and survival.
  • Comparison of major lymphocyte subpopulations and recent thymic emigrants in patients with ataxia telangiectasia and age-matched healthy groups.
  • Epstein-Barr Virus (EBV)-Related Lymphoproliferative Disorders in Ataxia Telangiectasia: Does ATM Regulate EBV Life Cycle?
  • Evaluation of Specific Antibody Responses in Patients with Selective IgA Deficiency and Ataxia Telangiectasia
  • Minimum effective betamethasone dosage on the neurological phenotype in patients with ataxia-telangiectasia: a multicenter observer-blind study.
  • Newborn screening for SCID identifies patients with ataxia telangiectasia.
  • Progressive Depletion of B and T Lymphocytes in Patients with Ataxia Telangiectasia: Results of the Italian Primary Immunodeficiency Network
  • Reconstitution of the Ataxia-Telangiectasia Cellular Phenotype With Lentiviral Vectors.
  • Treatment of Granulomas in Patients With Ataxia Telangiectasia.
  • Two Novel Mutations Associated With Ataxia-Telangiectasia Identified Using an Ion AmpliSeq Inherited Disease Panel.

Language

  Turkish (Turkey)
  • Hindi (India)
  • Hebrew
  • Arabic (اللغة العربية)
  • Turkish (Turkey)
  • 日本語 (Japan)
  • Russian (Russia)
  • Français (France)
  • Deutsch (Deutschland)
  • Español (España)
  • Nederlands (nl-NL)
  • Português Brasileiro (pt-BR)
  • Polski (PL)
  • Italiano (Italia)
  • English (United Kingdom)

Tweets by A_Tinfo

ataksi telenjiektazi
  • Başlangıç
  • A-T nedir?
  • admin@ataxiatelangiectasia.es